Level C· Early human research exploring benefitsProspective StudyPubMed

Bone Marrow Aspirate Concentrate (BMAC) Versus Adipose-Derived Stem Cells (ADSCs) Intra-articular Injection Therapeutic Efficacy in Knee OA Correlated to Their Mesenchymal Stem Cell (MSC) Cellularity: An Exploratory Comp

Vitali M., Ometti M., Montalbano F., Spadafora S., Di Micco R., Salini V.

Prospective Study with a reported sample of 60 on Knee Osteoarthritis, Osteoarthritis, Meniscus Injury, published in Indian J Orthop (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Indian J Orthop (2025)
Country
Switzerland
Reported sample size
60
Source database
PubMed
PMID
41394459
DOI
10.1007/s43465-025-01525-z
Citations
1

Abstract (original English)

Osteoarthritis (OA) is a chronic degenerative joint disease affecting millions of people mainly aged over 65. OA leads to progressive damage across joint components, including bone degeneration with osteophyte formation, cartilage erosion, synovitis, and meniscal deterioration. Early OA treatments focus on symptom management, but advanced knee OA often requires alternative approaches. Regenerative medicine, such as tissue engineering, offers promising solutions. Mesenchymal stem cell (MSC) intra-articular injections have gained popularity for OA management. Autologous sources, such as bone marrow aspirate concentrate (BMAC) and adipose-derived stem cells (ADSCs), are widely used. This study compared the therapeutic efficacy of single BMAC and ADSC injections in knee OA patients, focusing on MSC quantity and quality in harvested tissues. To support this, hematological studies analyzed and quantified CD34+ cells in adipose and bone marrow samples. 60 patients diagnosed with symptomatic degenerative knee OA were enrolled. Patients under 50 received BMAC injections, while those over 50 received ADSC injections. Follow-ups were conducted at baseline(t0), 1 month (t1), 3 months (t2), and 6 months (t3) using the Visual Analog Scale (VAS), WOMAC score, Kellgren-Lawrence classification, and range of motion (ROM). Bone marrow and adipose samples were harvested and processed to quantify v

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research